

Supplemental Table 1. Characteristics of Participating Sites

Site	Site Type	Census Region	Patient Cohort Included Members of a Special Population <sup>a</sup>	Data Collection Tier <sup>b</sup>	Patients Discontinuing Treatment (%)
A	State health department	South	Homeless	Comprehensive	15.1
B	Correctional facility	Northeast Midwest South West	Corrections	Basic	5.5
C	Mixed	West	Corrections, students	Standard	8.3
D	State health department	Northeast	Corrections, students	Standard	13.3
E	County health departments	South	Homeless, children	Basic	17.5
F	City health department	West		Standard	15.0
G	County health department	Midwest	Homeless	Basic	3.3
H	State health department, university health clinic	Midwest	Students	Comprehensive	9.3
I	University health clinic	Midwest		Standard	12.5
J	State health department	South	Homeless, children	Comprehensive	16.1
K	Health department	West		Comprehensive	9.8
L	County health departments	West		Comprehensive	19.2
M	Hospital	Midwest	Children	Basic	0.0
N	City health department	Midwest		Basic	11.8
O	State health department	South		Comprehensive	9.0
P	State health department	South		Basic	8.7
<b>Total</b>					<b>421 of 3288 (12.8)</b>

<sup>a</sup> Certain site populations included patients of particular interest for treatment with 3HP because the completion rates with daily isoniazid are historically low.

<sup>b</sup> Data collection tiers: basic tier data included patient demographics, weekly dose and ADRs, and final disposition; standard tier data included basic tier data plus certain medical and

population risk factors for TB and concomitant medications of specific medication classes;  
comprehensive tier data included all data collected in the standard tier plus additional patient  
medications and medical conditions.

Supplemental Table 2. Summary of Outcomes of 3HP Treatment (n=3288)

Final Disposition	No. (%)
Patient completed treatment without interruption	2,793 (84.9)
Patient temporary halted due to adverse drug reaction (ADRs) or other cause but subsequently completed treatment	74 (2.3)
Patient discontinued 3HP and switched to an alternate regimen <sup>a</sup> (ie, 9H, 6H, or 4R)	115 (3.5)
Patient discontinued because of ADR or adverse event and stopped all LTBI treatment <sup>b</sup>	131 (4.0)
Discontinuation as a result of loss to follow-up or refusal <sup>c</sup>	175 (5.3)

Abbreviations: 3HP, 3-month regimen of once-weekly isoniazid and rifapentine directly supervised; LTBI, latent TB infection

<sup>a</sup> Alternate regimens included a 9-month regimen of daily isoniazid (9H), a 6-month regimen of daily isoniazid (6H), and a 4-month regimen of daily rifampin (4R).

<sup>b</sup> Final disposition data indicated patient stopped because of adverse event or ADR(s); for certain patients no additional information was provided and the patient was presumed to have stopped all LTBI treatment.

<sup>c</sup> Loss to follow-up included patients who did not return for scheduled directly observed therapy visits, moved out of the site catchment area, moved out of state, were released from a corrections facility, transferred to another school, or refused to continue treatment.